Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution in COVID-19: Case Series

Camille Celeste Go, Krunal Pandav, Marcos A Sanchez-Gonzalez, Gustavo Ferrer, Camille Celeste Go, Krunal Pandav, Marcos A Sanchez-Gonzalez, Gustavo Ferrer

Abstract

The SARS-CoV-2 virus has created an unprecedented impact on healthcare globally. Being a novel virus, several treatments have been explored against COVID-19. During the early stages of the disease, treatment is mainly supportive. While several studies have suggested different treatment modalities, there is still no definitive treatment against COVID-19. Re-purposing already established medications, with excellent safety profiles, is a possible approach for treating the disease in its early stage. Having a mode of transmission as a droplet mode, several studies have supported how the nose can contain the primary route of entry of SARS-CoV-2. Hence, we postulated that re-purposing a commercially available nasal spray containing xylitol and grapefruit seed extract (GSE), namely Xlear Nasal Spray® (Xlear, Inc., American Fork, USA) could be used as an adjunct treatment of COVID-19. With a well-established safety profile, the components of this nasal spray have been studied and have been shown to have potential efficacy against viral pathogens, including coronavirus, and may potentially regulate pathways important in the initial entry of infection, replication, and systemic response to SARS-CoV-2. We present a series of three mild-moderate risks, symptomatic, COVID-19 patients, treated with the intranasal combination, as an adjuvant to their ongoing treatment, with rapid clinical improvement and shorten time to negativization on repeat intranasal swab test via PCR. No safety issues were noted during the course of treatment. Xlear nasal spray, containing xylitol plus GSE, given its established safety profile and compelling clinical results described here, could be a potential adjunct treatment option in mild-moderate COVID-19 cases.

Keywords: covid-19; grapefruit seed extract; intranasal; sars-cov-2; therapeutics; xylitol.

Conflict of interest statement

The authors have declared financial relationships, which are detailed in the next section.

Copyright © 2020, Go et al.

Figures

Figure 1. Chest X-ray image of patient…
Figure 1. Chest X-ray image of patient 3

References

    1. People with certain medical conditions. [Oct;2020 ]; 2020
    1. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [Oct;2020 ]; 2020
    1. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Sungnak W, Huang N, Bécavin C, et al. Nat Med. 2020;26:681–687.
    1. Sinonasal pathophysiology of SARS-CoV-2 and COVID- 19: a systematic review of the current evidence. Gengler I, Wang JC, Speth MM, Sedaghat AR. Laryngoscope Investig Otolaryngol. 2020;16:354–359.
    1. Iota-carrageenan and Xylitol inhibit SARS-CoV-2 in cell culture. [Oct;2020 ];Bansal S, Jonsson CB, Taylor SL, et al. bioRxiv. Published online January 1. 2020
    1. Inhibitory effect of grapefruit seed extract (GSE) on avian pathogens. Komura M, Suzuki M, Sangsriratanakul N, et al. J Vet Med Sci. 2019;81:466–472.
    1. Olfactory Dysfunction in COVID- 19: diagnosis and Management. Whitcroft KL, Hummel T. JAMA. 2020;323:2512–2514.
    1. Anemia is associated with severe coronavirus disease 2019 (COVID-19) infection [PREPRINT] Hariyanto TI, Kurniawan A. Transfus Apher Sci. 2020:102926.
    1. Nasal drug delivery in humans. Bitter C, Suter-Zimmermann K, Surber C. Curr Probl Dermatol. 2011;40:20–35.
    1. Dosimetry of nasal uptake of water-soluble and reactive gases: a first study of interhuman variability. Garcia GJ, Schroeter JD, Segal RA, Stanek J, Foureman GL, Kimbell JS. Inhal Toxicol. 2009;21:607–618.
    1. Anatomical and histological factors affecting intranasal drug and vaccine delivery. Gizurarson S. Current Drug Delivery. 2012;9:566–582.
    1. Intranasal drug delivery: how, why and what for? Pires A, Fortuna A, Alves G, Falcão A. J Pharm Pharm Sci. 2009;12:288–311.
    1. A novel fluorescent sensor protein for detecting changes in airway surface liquid glucose concentration. Helassa N, Garnett JP, Farrant M, et al. Biochem J. 2014;464:213–220.
    1. Anatomic and physiologic considerations in sinusitis. Wagenmann M, Naclerio RM. J Allergy Clin Immunol. 1992;90:419–423.
    1. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Hou YJ, Okuda K, Edwards CE, et al. Cell. 2020;182:429–446.
    1. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. Jia HP, Look DC, Shi L, et al. J Virol. 2005;79:14614–14621.
    1. Researchers map how coronavirus infection travels through cells of nasal cavity and respiratory tract. [Oct;2020 ]; 2020
    1. Prevalence and duration of acute loss of smell or taste in COVID-19 patients. Lee Y, Min P, Lee S, Kim SW. J Korean Med Sci. 2020;35:0.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa